Ken Griffin Morpho Sys Ag Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$17.36 - $19.34 $159,712 - $177,928
-9,200 Reduced 52.57%
8,300 $151,000
Q1 2024

May 15, 2024
SELL
$8.6 - $18.18 $38,700 - $81,810
-4,500 Reduced 20.45%
17,500 $317,000
Q4 2023

Feb 14, 2024
BUY
$4.55 - $9.9 $83,265 - $181,170
18,300 Added 494.59%
22,000 $217,000
Q3 2023

Nov 14, 2023
BUY
$6.72 - $8.6 $3,360 - $4,300
500 Added 15.63%
3,700 $24,000
Q2 2023

Aug 14, 2023
BUY
$3.95 - $7.74 $12,640 - $24,768
3,200 New
3,200 $23,000

Others Institutions Holding MOR

# of Institutions
13
Shares Held
1.8M
Call Options Held
0
Put Options Held
14.7K
View Full List

About MorphoSys AG

MOR Quotes by TradingView
  • Ticker MOR
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 136,614,000
  • Description
  • MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...
More about MOR
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email